ProQR Therapeutics NV, which is developing RNA therapeutics for genetic eye diseases, has appointed John Maraganore as a strategic advisor. Dr Maraganore is the former founding chief executive of Alnylam Pharmaceuticals Inc, a developer of RNA interference (RNAi) therapeutics. He led Alnylam for 19 years during which time the company discovered and commercialised four RNAi therapeutics. Prior to this, he was an executive at Millennium Pharmaceuticals Inc and Biogen Inc.
ProQR Therapeutics announced the appointment on 7 March 2022.
Copyright 2022 Evernow Publishing Ltd